Drug Trial Radar · NCT07873931
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Oct 20, 2032
Study completion Jan 31, 2033
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren's disease (SjD).
Conditions
- Systemic Lupus Erythematosus
- Sjögren's Disease
- Rheumatoid Arthritis
- Idiopathic Inflammatory Myopathies
- Systemic Sclerosis
- Lupus Nephritis
Interventions
BMS-986553Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment emergent adverse events (TEAEs)Time frame: Up to approximately 90 days post BMS-986553 infusion
- Number of participants with serious adverse events (SAEs)Time frame: Up to approximately 90 days post BMS-986553 infusion
- Number of participants with adverse events of special interest (AESIs)Time frame: Up to approximately 90 days post BMS-986553 infusion
- Number of participants with clinically significant laboratory abnormalitiesTime frame: Up to approximately 90 days post BMS-986553 infusion
- Number of participants with dose limiting toxicities (DLTs) that occur in DLT evaluation periodTime frame: 28 days after first infusion of BMS-986553
Locations
23 sites in 6 countries. Site status is shown where the registry gives one.
Local Institution - 0064
Newport Beach, California
Local Institution - 0001
Worcester, Massachusetts
Local Institution - 0004
Ann Arbor, Michigan
Local Institution - 0013
Saint Paul, Minnesota
Local Institution - 0062
Omaha, Nebraska
Local Institution - 0007
Morristown, New Jersey
Local Institution - 0052
Great Neck, New York
Local Institution - 0008
Philadelphia, Pennsylvania
Local Institution - 0015
Salt Lake City, Utah
Local Institution - 0005
Seattle, Washington
Local Institution - 0003
Seattle, Washington
Local Institution - 0029
Leuven, Belgium
Local Institution - 0039
Montpellier, France
Local Institution - 0047
Paris, France
Local Institution - 0028
Berlin, Germany
Local Institution - 0060
Erlangen, Germany
Local Institution - 0059
Magdeburg, Germany
Local Institution - 0027
Würzburg, Germany
Local Institution - 0063
Leiden, Netherlands
Local Institution - 0055
Amsterdam, North Holland, Netherlands
Local Institution - 0046
Poznan, Poland
Local Institution - 0051
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Local Institution - 0050
Krakow, Malopolwksie, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.